An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice.
PubWeight™: 0.80‹?›
Published in Kidney Int on June 02, 2016
Authors
Isis Ludwig-Portugall1, Eva Bartok2, Ermanila Dhana1, Beatrix D G Evers1, Michael J Primiano3, J Perry Hall3, Bernardo S Franklin4, Percy A Knolle5, Veit Hornung6, Gunther Hartmann7, Peter Boor8, Eicke Latz9, Christian Kurts10
Author Affiliations
1: Institute of Experimental Immunology, University Hospital of the Rheinische Friedrich-Wilhelms-University, Bonn, Germany.
2: Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital of the Rheinische Friedrich-Wilhelms-University, Bonn, Germany; Institute of Molecular Medicine, University Hospital of the Rheinische Friedrich-Wilhelms-University, Bonn, Germany.
3: Institute of Innate Immunity, University Hospital of the Rheinische Friedrich-Wilhelms-University, Bonn, Germany.
4: Inflammation and Immunology Research Unit, Pfizer Inc., Cambridge, Massachusetts, USA.
5: Institute of Molecular Immunology, Technische Universität München, Munich, Germany.
6: Institute of Molecular Medicine, University Hospital of the Rheinische Friedrich-Wilhelms-University, Bonn, Germany.
7: Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital of the Rheinische Friedrich-Wilhelms-University, Bonn, Germany.
8: Department of Nephrology, University of Aachen, Aachen, Germany.
9: Institute of Innate Immunity, University Hospital of the Rheinische Friedrich-Wilhelms-University, Bonn, Germany; Inflammation and Immunology Research Unit, Pfizer Inc., Cambridge, Massachusetts, USA; Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
10: Institute of Experimental Immunology, University Hospital of the Rheinische Friedrich-Wilhelms-University, Bonn, Germany. Electronic address: ckurts@web.de.
Articles by these authors ⇆